Evidence map›Paper›PMID 24067603›Full record

ArticleJournal of atherosclerosis and thrombosis2013

Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages.

Eugene O Apostolov, Ercan Ok, Samuel Burns, Safia Nawaz, Alena Savenka, Sudhir V Shah, Alexei G Basnakian

Open access · hybridAbstract read
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Carbamylated lipoproteins in diabetes.World journal of diabetes · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Reduction of carbamylated albumin by extended hemodialysis.Hemodialysis international. International Symposium on Home Hemodialysis · 2016
    Article
  17. Review
  18. The role of CD36 in renal and bladder cancer.Discoveries (Craiova, Romania)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Eugene O ApostolovDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences.
Ercan Ok
Samuel Burns
Safia Nawaz
Alena Savenka
Sudhir V Shah
Alexei G Basnakian
University of Arkansas for Medical Sciences · US

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett, JERRY WARE · 2012 to 2026
$60.9M
VIRULENCE MECHANISMS IN ESCHERICHIA COLIP20RR016460 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI HENSLEY, LORI · 2001 to 2011
$33.1M
Premortem enzymatic DNA damage in kidney injuryR01DK078908 · NIDDK · UNIV OF ARKANSAS FOR MED SCIS · PI BASNAKIAN, ALEXEI G · 2008 to 2012
$1.5M
LDL isoforms in kidney-related atherosclerosisvR21HL087405 · NHLBI · UNIV OF ARKANSAS FOR MED SCIS · PI BASNAKIAN, ALEXEI G · 2008 to 2009
$363k
NCRR NIH HHS 5P20RR016460-11NCRR NIH HHS P20 RR016460NHLBI NIH HHS R21 HL087405NIDDK NIH HHS R01 DK078908NIGMS NIH HHS 8 P20 GM103429-11NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

aimBoth oxidized LDL and carbamylated LDL are considered important for initiating atherosclerosis in patients with end-stage kidney disease through vascular endothelial cell dysfunction or injury. However their effects on each other and their relationship related to pro-atherosclerotic effects on endothelial cells and macrophages have not been investigated. In this study, we analyzed the competition between LDL carbamylation and oxidation, tested biological effects of carbamylated-oxidized LDL (coxLDL) toward the endothelial cells, assessed its ability to cause foam cell development, and determined the roles of scavenger receptors in this process.

methodsCross-competition between carbamylation and oxidation of LDL particles was tested using cell-free fluorescent ligand-receptor assay. Pro-atherogenic properties (cell proliferation, cytotoxicity, and foam cell formation) of all LDL isoforms were tested in vitro and ex vivo using endothelial cells and peritoneal macrophages. In addition, coxLDL was assessed in human sera and in vivo atherosclerotic plaques which were developed in mouse model of uremia-induced atherosclerosis.

resultsOur data suggest that there is potential competition between carbamylation and oxidation of LDL, and that oxidation is a much stronger inhibitor of carbamylation than vice versa. coxLDL is highly cytotoxic to endothelial cells and strongly induce their proliferation measured by DNA synthesis. All three tested LDL isoforms demonstrated strong ability for transformation of primary mouse peritoneal macrophages to foam cells using predominantly CD36 scavenger receptor. coxLDL was the most potent inducer of foam cell development and macrophages/foam cell injury assessed by cell count and TUNEL, respectively. Finally, LDL particles modified by oxidation and carbamylation were detected in blood and shown to co-localize in atherosclerotic plaques in mice.

conclusionOur study demonstrated that LDL particles can be simultaneously carbamylated and oxidized and modifications are likely coexisting in the same LDL particle. We also demonstrated proatherosclerotic properties of coxLDL and proposed its role in atherosclerosis.

Indexed as

AtherosclerosisCarbamatesCell DeathCells, CulturedEndothelium, VascularEnzyme-Linked Immunosorbent AssayHumansIn Situ Nick-End LabelingLipoproteins, LDLMacrophagesOxidation-ReductionCarbamatescarbamic acidLipoproteins, LDLoxidized low density lipoprotein

Identifiers

PMID24067603
PMCPMC5345570
OpenAlexW2079754271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.